LIVZON PHARMAC. GRP H YC1 (LP6) — Net Asset Momentum

Latest YoY growth as of December 2025: +4.3%

LIVZON PHARMAC. GRP H YC1 (LP6) recorded a net asset momentum of 4.3% as of December 2025, with net assets of €15.55 Billion EUR. Net Asset Momentum measures the year-over-year percentage change in net assets (total assets minus total liabilities), indicating how rapidly the company is building or eroding its equity base. See LIVZON PHARMAC. GRP H YC1 (LP6) liquidity interval to measure how many days the company can operate on defensive assets alone.

YoY Momentum

+4.3%
Year-over-year

Current Net Assets

€15.55 Billion
EUR · December 2025

Years of Data

5
2021 – 2025

Country

Germany
F

LIVZON PHARMAC. GRP H YC1 Net Asset Momentum (2021–2025)

This chart tracks LIVZON PHARMAC. GRP H YC1's year-over-year net asset growth across 5 annual reporting periods from 2021 to 2025. The most recent momentum reading is +4.3%, with net assets of €15.55 Billion EUR as of December 2025. Read LIVZON PHARMAC. GRP H YC1 (LP6) total liabilities for a breakdown of total debt and financial obligations.

Annual Net Asset History for LIVZON PHARMAC. GRP H YC1 (2021–2025)

The table below shows the complete annual net asset history for LIVZON PHARMAC. GRP H YC1 from 2021 to 2025, covering 5 yearly periods. Each row includes total assets, total liabilities, net assets, and the year-over-year momentum figure for that period. For live market cap and broader valuation context, see LP6 market cap overview.

Year Net Assets (EUR) Total Assets Total Liabilities YoY Momentum
2025 €15.55 Billion €23.99 Billion €8.44 Billion ▲ +4.3%
2024 €14.91 Billion €24.46 Billion €9.55 Billion ▲ +0.9%
2023 €14.77 Billion €25.04 Billion €10.28 Billion ▼ -1.1%
2022 €14.94 Billion €24.87 Billion €9.93 Billion ▲ +4.4%
2021 €14.31 Billion €22.37 Billion €8.06 Billion